CCR5-ligand decorated rilpivirine lipid-based nanoparticles for sustained antiretroviral responses
Abstract Antiretroviral therapy (ART) improves the quality of life for those living with the human immunodeficiency virus type one (HIV-1). However, poor compliance reduces ART effectiveness and leads to immune compromise, viral mutations, and disease co-morbidities. Here we develop a drug formulati...
Saved in:
Main Authors: | Milankumar Patel, Sudipta Panja, Lubaba A. Zaman, Pravin Yeapuri, Shaurav Bhattarai, Santhi Gorantla, Linda Chang, Alonso Heredia, Piotr Walczak, Brandon Hanson, Samuel M. Cohen, Bhavesh D. Kevadiya, Howard E. Gendelman |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-024-55544-9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH in clinical need: 52 weeks real-world data
by: Valentina Iannone, et al.
Published: (2025-01-01) -
CCR9 Antagonists in the Treatment of Ulcerative Colitis
by: Pirow Bekker, et al.
Published: (2015-01-01) -
SOME CONSIDERATIONS REGARDING CCR DEC. NO. 364/2022
by: Marta-Claudia CLIZA
Published: (2024-05-01) -
A novel CCR5 mutation common in sooty mangabeys reveals SIVsmm infection of CCR5-null natural hosts and efficient alternative coreceptor use in vivo.
by: Nadeene E Riddick, et al.
Published: (2010-08-01) -
Eradication of HIV by Transplantation of CCR5-Deficient Hematopoietic Stem Cells
by: Gero Hütter, et al.
Published: (2011-01-01)